Aerovate Therapeutics (AVTE) Expected to Announce Earnings on Monday

Aerovate Therapeutics (NASDAQ:AVTE) is expected to be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Aerovate Therapeutics to post earnings of ($0.40) per share for the quarter.

Aerovate Therapeutics Price Performance

NASDAQ AVTE opened at $2.52 on Friday. The stock has a market capitalization of $72.77 million, a P/E ratio of -0.84 and a beta of 1.01. The business has a 50 day simple moving average of $2.49 and a 200 day simple moving average of $2.42. Aerovate Therapeutics has a one year low of $1.25 and a one year high of $32.42.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.